Board of Directors

Roy Baynes has served as a member of our board of directors since July 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.

Roelof F. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a Managing Member of Sequoia Capital Operations, LLC since 2007.From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., most recently as the Chief Financial Officer. From 1996 to 1998, Mr. Botha served as a management consultant for McKinsey & Company, a management consulting firm. Mr. Botha currently serves on the board of directors of Square, Inc. (NYSE: SQ), a provider of payments, financial and marketing services; MongoDB, Inc. (Nasdaq: MDB), a document oriented database program developer; Eventbrite, Inc. (NYSE: EB), an event management and ticketing platform; Unity, Inc. (NYSE: U), a 3D and VR content development platform, and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University.

Rowan Chapman has served as a member of our board of directors since August 2019. Dr. Chapman is a founder, investor, and active independent board member of various companies. She most recently held senior roles as Head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand, and as Head of Precision Diagnostics at GE Healthcare Life Sciences, Managing Director of New Business Creation, and Head of Healthcare Investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of tech and data-enabled companies. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom.

Steve Chapman is the chief executive officer of Natera, a global leader in cell-free DNA and genetic testing in oncology, women’s health and organ health. He also serves on the company’s board of directors.

Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease; the Prospera™ transplant assessment test; the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease; and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.

Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis.

In 2024, Chapman was named one of the top healthcare technology CEOs by Healthcare Technology Report, as well as “BioTechnology Innovator of the Year” by BioTech Breakthrough. He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. Chapman has also authored multiple scientific papers.

He holds a BS in Microbiology, Immunology, and Molecular Genetics from UCLA, where he graduated with honors. 

James I. Healy has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently the Chairman of CinCor (CINC) and of Y-mAbs (YMAB), a member of the board of directors for Atsena, Karuna (KRTX), the lead independent director of Bolt (BOLT) and a board observer at Visen. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.

Gail Marcus has served as a member of our board of directors since March 2017. Dr. Marcus is currently an Assistant Professor and Executive in Residence at the Massachusetts College of Pharmacy and Health Sciences. Prior to academia, Dr. Marcus was a healthcare executive across a diverse portfolio of healthcare organizations in the US and UK, including Cigna, UnitedHealthcare Group Inc., CVS/Caremark, and Caris Diagnostics of Caris Life Sciences. In 2014, she was selected as one of the top 100 women executives in Massachusetts. Dr. Marcus currently serves on the boards of directors of another public company, a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Dr. Marcus holds a Doctorate of Health Administration from the Medical University of South Carolina. She received a B.A. in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School Of Engineering and a M.B.A. from the Wharton School of the University of Pennsylvania.

Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2019. He serves as a chairman, director or adviser to many companies and nonprofits involved in diagnostics, biotech, AI, health services and nature conservation and manages an early stage technology venture fund focused on biotech, security and AI. Companies he founded have twice received the World Economic Forum Technology Pioneer award, given in those years to 20 companies worldwide, and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford and visiting faculty in Genetics at Harvard and received the Scott Helt Award from IEEE. He has authored over 100 patents and publications respectively, including papers in the top reproductive, transplant and oncology journals, SCIENCE and Nature (cover). He has led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management; a technology that tracks an individual patient’s tumor mutations in blood that has transformed cancer management with multiple FDA breakthrough designations; and the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children and other breakthrough products. He was named R&D Leader of the Year by R&D World in 2024. Dr Rabinowitz studied EE and Physics at Stanford, receiving the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed a PhD in Electrical Engineering.

Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.

Jonathan Sheena is a co-founder of our company. Mr. Sheena has served as a member of our board of directors since 2007, and served as our Chief Technology Officer from 2007 to December 2020. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, Inc. including vice president of product management and chief technology officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology.

Ruth E. Williams-Brinkley joined our board of directors in March 2023. Williams-Brinkley is a veteran healthcare executive who currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), overseeing the company’s care delivery and health plan operations in Washington, D.C., suburban Maryland, Baltimore, and Northern Virginia. She was previously president of Kaiser Foundation Health Plan and Hospitals of the Northwest, CEO of KentuckyOne Health, president and CEO of Carondelet Health Network in Tucson, Arizona, and president and CEO of Memorial Healthcare System in Chattanooga, Tennessee. Williams-Brinkley serves on the boards of Travere Therapeutics, DePaul University, the Greater Washington Board of Trade, and the Northern Virginia Trade of Commerce. She holds both a bachelor’s degree and Master of Science degree in nursing from DePaul University.